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Bethanidine Sulfate: Efficacy in Prevention of Ventricular 
Tachyarrhythmias During Programmed Stimulation. Report of a 
Multicenter Study of 56 Patients 
SAM L. TEICHMAN, MD, LAWRENCE E. WASPE, MD, FACC, JEFFREY A. MATOS, MD, 
SOO G. KIM, MD, FACC, JOHN D. FISHER, MD, FACC and participating members of a 
MULTICENTER BETHANIDINE STUDY* 
Bronx. New York 
Twelve cardiac electrophysiology centers conducted an 
open label prospective trial of bethanidine sulfate, an 
oral bretylium analog, for the prevention of ventricular 
tachyarrhythmias during programmed electrical stim-
ulation. The study group included 56 patients (44 men, 
12 women; mean age 60 years; 55 with structural heart 
disease). Sixteen patients had both ventricular tachy-
cardia and fibrillation, 30 had ventricular tachycardia 
alone and 10 had ventricular fibrillation alone. Pro-
grammed stimulation on no antiarrhythmic drugs in-
duced sustained ventricular tachycardia in 46 patients, 
nonsustained ventricular tachycardia in 4 patients and 
ventricular fibrillation in 6 patients. 
During programmed ventricular stimulation after 59 
trials of 20 to 30 mg/kg body weight of oral bethanidine 
(acute dosing in 40 patients, and divided dosing over 24 
hours in 19 patients), no ventricular tachyarrhythmias 
were inducible in 6 patients (11 %), sustained ventricular 
tachycardia was converted to nonsustained ventricular 
tachycardia in 3 patients (5%), ventricular tachyar-
Bethanidine sulfate has a chemical structure and pharma-
cologic properties similar to those of bretylium tosylate with 
the additional characteristic of adequate absorption after oral 
administration (1). In dogs, bethanidine has been shown to 
increase the ventricular fibrillation threshold (2). In vivo, it 
has been reported to treat successfully recurrent ventricular 
tachyarrhythmias, especially ventricular fibrillation, that are 
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rhythmias remained inducible in 39 patients (70%) and 
spontaneous ventricular tachyarrhythmias occurred more 
frequently in 4 patients (7%). Side effects prevented 
repeat testing in four patients. The 10 patients presenting 
with only ventricular fibrillation appeared to have a higher 
response rate: no ventricular tachyarrhythmias were in-
ducible in 2 patients and sustained ventricular tachy-
cardia was converted to nonsustained ventricular tachy-
cardia in 2 patients. Despite protriptyline administration 
in 54 of 59 bethanidine trials, symptomatic hypotension 
occurred in 30 trials (51 %). 
In conclusion, the efficacy of bethanidine for pre-
venting ventricular tachyarrhythmias as assessed by 
programmed stimulation is low. Patients presenting with 
only ventricular fibrillation may have a more favorable 
response to bethanidine sulfate. Symptomatic hypoten-
sion occurs frequently despite concomitant use of 
protriptyline. 
(J Am Coll CardioI1985;6:51O-7) 
refractory to conventional therapy (3-6). Orthostatic hy-
potension is a major side effect of bethanidine, but studies 
have indicated that the concurrent administration of a tri-
cyclic antidepressant, usually protriptyJine, can minimize 
this problem (3-7). In this report we present the results of 
a prospective, multicenter trial that evaluated the effective-
ness and safety of bethanidine therapy combined with pro-
triptyline for the prevention of ventricular tachyarrhythmias 
induced by programmed electrical stimulation. 
Methods 
Study design. From April 1982 to April 1983, twelve 
cardiac electrophysiology centers participated in an open 
label, prospective trial involving patients undergoing pro-
grammed electrical stimulation for management of out-of-
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hospital cardiac arrest, documented ventricular fibrillation 
or life-threatening ventricular tachycardia. Baseline ven-
tricular stimulation was carried out to determine vulnera-
bility to induction of ventricular tachyarrhythmias. Stimu-
lation was repeated after beth ani dine administration to 
document the effects on the induction of ventricular 
tachyarrhythmias. 
Patient selection. Inclusion criteria. At each partici-
pating institution, patients requiring invasive electrophysi-
ologic evaluation for management of recurrent sustained 
ventricular tachycardia or primary ventricular fibrillation 
were eligible for inclusion in this study. During baseline 
electrophysiologic studies, either ventricular fibrillation or 
ventricular tachycardia of a configuration similar to that of 
the spontaneous arrhythmia was inducible. 
Exclusion criteria. Patients were excluded from this study 
if they were unable to undergo baseline electrophysiologic 
assessment while receiving no antiarrhythmic agents. They 
were excluded if they had I) a myocardial infarction within 
the preceding 6 weeks, 2) unstable angina pectoris, 3) Wolff-
Parkinson-White syndrome, 4) cardiogenic shock or hy-
potension requiring pharmacologic support, or 5) electrolyte 
disturbances. Patients receiving monoamine oxidase inhib-
itors, tricyclic antidepressants or sympathomimetic drugs 
were also excluded. 
Programmed electrical stimulation technique. Pro-
grammed electrical stimulation was carried out in a similar 
manner during the baseline period and after bethanidine 
administration. Baseline stimulation was performed after all 
antiarrhythmic agents had been discontinued for a minimum 
of three to five drug half-lives. One, two and then three 
extrastimuli were delivered in the right ventricle with in-
creasing prematurity until ventricular refractoriness was 
reached or until ventricular tachycardia or ventricular fi-
brillation was induced. These extrastimuli were delivered 
during sinus rhythm and at one to two ventricular pacing 
rates at one to two right ventricular sites. If ventricular 
tachyarrhythmias were not induced by programmed extra-
stimuli, bursts of ventricular pacing (10 to 20 beats) were 
performed in the right ventricle at rates of up to 250 beats/min. 
In one patient in whom right ventricular stimulation failed 
to induce ventricular tachycardia or fibrillation, left ven-
tricular stimulation was carried out using the same protocol. 
Isoproterenol was not administered as part of this study. 
The end point of stimulation in all cases was induction 
of ventricular tachycardia or ventricular fibrillation or com-
pletion of the stimulation protocol. Sustained ventricular 
tachycardia was defined as ventricular tachycardia requiring 
pacing or cardioversion for termination. Nonsustained ven-
tricular tachycardia was defined as ventricular tachycardia 
of 10 or more beats' d!Jration which terminated sponta-
neously. No arbitrary duration of ventricular tachycardia 
was utilized to distinguish between nonsustained and sus-
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tained ventricular tachycardia. For a patient to be eligible 
for beth ani dine testing, a reproducible nonsustained ven-
tricular tachycardia had to be induced at least twice during 
the baseline study. 
Bretylium has been reported to be less effective at low 
serum potassium levels and it has been suggested that be-
thanidine shares this property (2,8). Therefore, no patient 
underwent stimulation with a serum potassium level below 
the lower limit of normal for any institution. 
Medication administration. Bethanidine. After the 
baseline electrophysiologic study, bethanidine was orally 
administered in one of two ways: acutely in one or two 
doses given just before testing or more chronically in divided 
doses for at least 24 hours before testing. Acute dose loading 
consisted of 10 mg/kg given 60 to 90 minutes before study. 
If ventricular tachycardia or ventricular fibriIlation remained 
inducible during programmed stimulation at this dose, pa-
tients could receive a second dose of 10 mg/kg (increasing 
the total loading dose to 30 mg/kg) and stimulation was 
repeated 60 to 90 minutes later. Divided dose loading con-
sisted of a total of 20 mg/kg daily given in divided doses 
every 6 to 8 hours for at least 24 hours before study. Patients 
receiving divided doses could receive an additional dose of 
bethanidine (5 to 20 mg/kg) 60 to 90 minutes before the 
time of testing at the discretion of the investigator. If be-
thanidine was believed to be clinically effective, patients 
continued receiving the drug at the discretion of the 
investigator. 
Protriptyline. Protriptyline was administered orally either 
as a single dose or as multiple doses before or during admin-
istration of bethanidine. Single dose administration con-
sisted of 10 to 15 mg given with bethanidine 60 to 90 minutes 
before programmed stimulation. Multiple dose protriptyline 
administration consisted of a total of 30 to 45 mg daily in 
divided doses for 1 to 3 days before or during bethanidine 
administration. 
Each patient gave informed written consent before re-
ceiving treatment as part of this study. The protocol was 
approved by the Human Studies Committee of each partic-
ipating institution. 
Classification of responses. Each patient served as his 
or her own control. Comparison of programmed stimulation 
in the baseline period and after bethanidine administration 
generated one of the responses defined below: 
Complete response. During programmed stimulation after 
the administration of bethanidine, neither ventricular fibril-
lation nor ventricular tachycardia (> 10 beats) was induced 
despite completion of the maximal stimulation protocol. 
Partial response. Sustained ventricular tachycardia in-
duced during baseline stimulation was converted to a non-
sustained, well tolerated ventricular tachycardia during 
stimulation after bethanidine. 
No response. Ventricular tachyarrhythmias similar to those 
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induced during baseline stimulation remained inducible after 
bethanidine administration. 
Adverse response. While the patient was receiving be-
thanidine, spontaneous ventricular tachyarrhythmias oc-
curred more frequently than during the baseline state. 
Statistical methods. Numerical data are expressed as 
mean values ± SD. Statistical comparisons were carried 
out using chi-square analysis with Yates' correction, R x 
C contingency tables or Fisher's exact test as appropriate. 
Results 
Patient population. A total of 59 clinical trials with 
bethanidine were carried out in 56 patients (mean 5 patients 
per participating center; range I to 14). There were 44 men 
and 12 women with a mean age of 60 ± 10 years (range 
26 to 80). Sixteen patients (29%) presented with a docu-
mented history of both sustained ventricular tachycardia and 
ventricular fibrillation, 10 patients (18%) presented with 
ventricular fibrillation alone and 30 patients (54%) presented 
with sustained ventricular tachycardia alone. 
Structural heart disease was present in all but I of the 
56 patients asfollows: coronary artery disease in 46 patients, 
valvular heart disease in 5 patients (including mitral valve 
prolapse in 2) and cardiomyopathy in 4 patients. Thirty-
eight patients had had a previous myocardial infarction and 
18 had a history of congestive heart failure. Sixteen patients 
were reported to have cardiomegaly and II had a left ven-
tricular aneurysm. The patients had a mean New York Heart 
Association functional class of 1.4. The mean left ventric-
ular ejection fraction, determined by radionuciide scintig-
raphy or cardiac catheterization in 45 patients, was 38 ± 
16% (range 8 to 75). 
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Prior antiarrhythmic agents had failed to control ventric-
ular tachyarrhythmias adequately in all patients with a mean 
of 3.9 drugs (range I to 8) tested per patient. Bretylium had 
been tested in nine patients and was successful in controlling 
arrhythmias in only three. 
Baseline electrophysiologic study (Table 1). During 
initial programmed electrical stimulation the following ven-
tricular tachyarrhythmias were induced: sustained ventric-
ular tachycardia in 46 patients (including ventricular tachy-
cardia that degenerated into ventricular fibrillation in 4 patients) 
and primary ventricular fibrillation in 6 patients. In addition, 
the following nonsustained ventricular tachycardias were 
induced in one patient each: 44 beats of monomorphic ven-
tricular tachycardia; 40 beats of polymorphic ventricular 
tachycardia; 39 seconds of monomorphic ventricular tachy-
cardia and reproducible nonsustained ventricular tachycar-
dia reported as more than 10 beats in duration. Left ven-
tricular stimulation was utilized in only one patient and 
resulted in the induction of sustained ventricular tachycardia. 
Programmed Stimulation After 
Bethanidine Administration 
Acute dose bethanidine loading (Table 2). In 40 trials, 
patients received the single acute oral dose of 20 mg/kg of 
bethanidine 60 to 90 minutes before repeat stimulation. Nei-
ther ventricular tachycardia nor ventricular fibrillation was 
inducible (complete response) in 3 (8%) of 40 patients, 
sustained ventricular tachycardia was converted to nons us-
tained ventricular tachycardia (partial response) in 3 pa-
tients, sustained ventricular tachycardia or ventricular fi-
brillation remained inducible (no response) in 33 patients 
(83%) and spontaneous ventricular tachyarrhythmias oc-
curred more frequently (adverse response) in 1 patient. In 
addition, in 23 of 33 patients who had no response to the 
20 mg/kg dose, an additional acute dose of 10 mg/kg was 
Table 1. Results of Bethanidine Testing According to Presenting Arrhythmia 
VF VT VT and VF All Patients 
Presenting Arrhythmia (n = (0) (n = 30) (n = (6) (n = 56) 
Baseline PES VT-S VF VT-NS VT-S VT-NS VT-S VF VT-NS VT-S VF VT-NS 
(no. of patients) (6) (3) (I) (29) (I) (12) (2) (2) (47) (5) (4) 
PES after bethanidine 
No. of patients(trials) 6 3 I 29(31) 12(13) 2 2 47(50) 5 4 
Complete response* 0 4 0 0 0 0 5 0 
Partial responset 0 1(3) 0 O(l)tt 0 0 2(5) I 0 
No responset 3 I 21 0 II I 35 2 2 
Adverse response§ I 0 0 2 I 0 0 0 3 0 
Not done** 0 0 0 0 2 
*Complete response = no inducible ventricular tachycardia or ventricular fibrillation; tPartial response = conversion of inducible sustained ventricular 
tachycardia to nonsustained ventricular tachycardia; :j:No response = no change in induced arrhythmia; §Adverse response = more frequent spontaneous 
ventricular tachyarrhythmias; **Not done = side effects precluded repeat programmed electrical stimulation. ttOne patient had no response to an initial 
trial of bethanidine and a partial response during a subsequent trial. PES = programmed electrical stimulation; VF = ventricular fibrillation; VT = 
ventricular tachycardia; VT-NS = nonsustained ventricular tachycardia (2: 10 beats and terminating spontaneously); VT-S = sustained ventricular 
tachycardia (requiring pacing or cardioversion for termination). 
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administered (total of 30 mg/kg) and stimulation repeated 
60 to 90 minutes later. Only one more patient had a complete 
response and two more had partial responses; however, three 
patients developed spontaneous ventricular tachycardia (ad-
verse response). 
Divided dose bethanidine loading (Table 2). In 19 trials, 
which included three patients who were also tested with a 
single acute dose of bethanidine, patients received divided 
doses of bethanidine for I to 8 days before undergoing repeat 
programmed electrical stimulation (five patients received 
more than 4 days of bethanidine treatment). Fourteen pa-
tients received 20 mg/kg daily, two received 15 mg/kg daily, 
one received 40 mg/kg daily and two who initially received 
20 mg/kg daily subsequently were given 10 and 15 mg/kg 
daily because of side effects. In addition, four of these 
patients received a supplemental dose of bethanidine (5 to 
20 mg/kg) at the time of electrophysiologic testing. The 
results of stimulation after divided dose bethanidine loading 
in 19 patients were as follows: 2 patients each (II % each) 
had complete and partial responses, II patients (58%) had 
no response and in 4 patients (21 %) stimulation was not 
repeated because of intolerable side effects. 
The four patients receiving less than 20 mg/kg daily re-
sponded as follows: sustained ventricular tachycardia was 
converted to nonsustained ventricular tachycardia in one 
patient, ventricular tachycardia remained inducible in one: 
two patients were not retested because of side effects. 
Patients with documented ventricular fibrillation (Ta-
ble 1). The results of programmed stimulation after be-
thanidine administration in the 27 trials in 26 patients with 
documented ventricular fibrillation (both with and without 
a history of ventricular tachycardia) were as follows: neither 
ventricular tachycardia nor ventricular fibrillation was in-
ducible in 2 patients (complete response) (7%); induced 
sustained ventricular tachycardia was converted to nonsus-
tained ventricular tachycardia (partial response) in 3 patients 
Table 2. Results of Bethanidine Testing According to 
Bethanidine Dosages 
Acute Acute Divided 
Dose Dose Dose 
Loading Loading Loadingt 
(20 mg/kg) (30 mg/kg) (20 mg/kg) 
Number of trials 40 23* 19 
Response:j: 
Complete response 3 (8%) 1 WId 2 (] 1%) 
Partial response 3 (8%) 2 (9%) 2 (110;;;) 
No response 33 (83%) 17 (74%) 11 (58%) 
Adverse response 1(3%) 3 (13%) 0 
Not done 0 0 4 (21%) 
*The 23 patients who received 30 mg/kg represent a subgroup of the 
33 patients who demonstrated no response to 20 mg/kg; t20 mg/kg daily 
in divided doses for at least 24 hours. :j:Responses are defined in Table I. 
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(II %); ventricular tachycardia or ventricular fibrillation re-
mained inducible (no response) in 18 patients (67%) and 
spontaneous ventricular tachycardia occurred in 1 patient 
during bethanidine administration (adverse response). Three 
patients (11 %) were not retested because of side effects. 
The subgroup of 10 patients presenting with isolated ven-
tricular fibrillation responded as follows: 2 patients (20%) 
had a complete response, 2 (20%) had a partial response, 
5 (50%) had no response and 1 had an adverse response. 
Patients with documented ventricular tachycardia 
(Table 1). The results of programmed stimulation in the 
32 trials in 30 patients with documented ventricular tachy-
cardia but no ventricular fibrillation were as follows: com-
plete response in 4 patients (13%), partial response in 3 
patients (9%), no response in 21 patients (66%) and adverse 
response in 3 patients; I patient was not retested because 
of side effects. 
All patients (Table 1). The results of programmed elec-
trical stimulation after bethanidine administration in the group 
as a whole can be summarized as follows: no ventricular 
tachyarrhythmia was inducible (complete response) in 6 (11 %) 
of 56 patients; sustained ventricular tachycardia was con-
verted to nonsustained ventricular tachycardia (partial re-
sponse) in 3 patients (5%); ventricular tachycardia or ven-
tricular fibrillation remained inducible (no response) in 39 
patients (70%); spontaneous ventricular tachyarrhythmias 
occurred more frequently (adverse response) in 4 patients 
(7%): 4 patients were not retested because of intolerable 
side effects. The three patients who were tested on both 
acute and divided dose loading of bethanidine had partial 
responses during both trials. 
Side effects (Table 3). Side effects occurred in 33 (59%) 
of 56 patients. The most common side effect during be-
thanidine therapy was symptomatic orthostatic hypotension, 
which occurred in 30 (54%) of the patients. Nausea and 
vomiting occurred in six patients, flushing caused by pe-
ripheral vasodilation in three and headache, rash and chest 
pain in one patient each. 
Protriptyline was administered during 54 (92%) of 59 
patient-trials. In the 40 trials of acute dose bethanidine (20 
to 30 mg/kg), 14 patients received acute protriptyline and 
21 received chronic protriptyline before bethanidine. In all 
19 trials of divided dose bethanidine, multiple doses of 
protriptyline were administered. Protriptyline was admin-
istered as either a single dose of 10 to 15 mg or as 30 to 
45 mg/kg daily in divided doses except in four patients who 
received more than 45 mg daily (60 mg daily in two patients 
and 80 and 120 mg daily in one patient each). Four patients 
had side effects attributable to protriptyline: anticholinergic 
effects (dry mouth, urinary hesitancy or retention) in three 
patients and acute confusion in one patient. 
The following observations were made concerning ther-
apy with bethanidine and protriptyline: 
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Table 3. Incidence of Orthostatic Hypotension According to Bethanidine Dosages 
Acute Acute Divided 
Dose Dose Dose 
Loading* Loading* Loading* All 
(20 mg/kg) (30 mg/kg) (20 mg/kg) Trials 
No. of trials 17 23 19 59 
No. with hypotension 6 (35%) 14 (61%) 10 (53%) 30 (51%) 
Protriptyline therapyt 
Single dose (10 to 15 mg) I 8 0 9 
Chronic dose (30 to 45 mg daily) 4 3 10 17 
None I 3 0 4 
No. without hypotension II (65%) 9 (39%) 9 (47%) 29 (49%) 
Protriptyline therapyt 
Single dose (10 to 15 mg) I 4 0 5 
Chronic dose (30 to 45 mg daily) 9 5 9 23 
None 0 0 
*Patient groups as defined in Table 2. tProtriptyline was administered as either a single dose of 10 to 15 
mg during bethanidine treatment 60 to 90 minutes before electrophysiologic testing, or as a chronic dose of 
30 to 45 mg daily in divided doses for I to 3 days before or during bethanidine treatment. 
I) The overall incidence of orthostatic hypotension was 
comparable whether patients received acute or divided dose 
bethanidine therapy: 20 (50%) of 40 patients who received 
one or more acute loading doses and 10 (53%) of 19 patients 
who received divided doses developed orthostatic hypoten-
sion (p = NS). 
2) Among the patients who received a single loading 
dose of bethanidine, the addition of a second loading dose 
increased the incidence of hypotension, but not significantly: 
6 (35%) of 17 patients who received 20 mg/kg and 14 (61 %) 
of 23 patients who received 30 mg/kg developed hypoten-
sion (p = NS). 
3) Among patients who received acute loading doses of 
bethanidine, the incidence of hypotension was decreased if 
they received chronic protriptyline as compared with acute 
protriptyline: 9 (64%) of 14 patients who received acute 
protriptyline and 7 (33%) of 21 patients who received chronic 
protriptyline developed hypotension. However, this differ-
enc.e was not statistically significant. 
4) Four of the five patients who did not receive protrip-
tyline developed orthostatic hypotension in response to 
bethanidine. 
Long-term bethanidine treatment. Two patients who 
had complete responses to programmed stimulation on be-
thanidine (one received acute and one received divided dose 
loading) have continued long-term therapy. They have re-
ceived bethanidine (20 mg/kg daily in divided doses) and 
protriptyline (45 and 60 mg daily for 6 and 14 months, 
respectively, at this writing): the regimen was considered 
effective for the prevention of recurrent ventricular tachy-
arrhythmias in both patients. Both patients had side effects 
attributable to the drugs: dizziness attributable to bethani-
dine in one patient and dry mouth and constipation attrib-
utable to protriptyline in one patient each. 
Discussion 
The initial work with "antiadrenergic" agents that led 
to the discovery of bretylium was done in England in the 
1950s and early 1960s (9). At that time, many related com-
pounds were also studied, including bethanidine (9). These 
studies showed that tolerance to the hypotensive effects of 
bethanidine does not occur as it does with bretylium (9). 
Thus, the early clinical use of bethanidine was as an anti-
hypertensive agent (10-13). The recent successful use of 
bretylium as an intravenous agent for ventricular fibrillation, 
however, has prompted a search for a comparable agent that 
is well absorbed orally and is suitable for chronic mainte-
nance therapy. 
Bethanidine lacks the polar quaternary nitrogen that pre-
vents bretylium from being absorbed from the gastrointes-
tinal tract. Absorption has been reported (14) to be essen-
tially complete with peak blood levels attained 1.5 to 2.5 
hours after ingestion. Plasma levels of bethanidine were not 
measured in this study; however, the doses administered 
correspond to the upper limits found effective and tolerable 
in two previous dose-ranging studies (3,4). 
The present study was undertaken to evaluate the effec-
tiveness of bethanidine in the treatment of ventricular ar-
rhythmias as assessed by programmed electrical stimulatjon. 
The use of programmed stimulation as a provocative test of 
the efficacy of antiarrhythmic agents in the treatment of 
ventricular tachycardia and ventricular fibrillation has been 
well established (15-19). Patients whose arrhythmias re-
main inducible during stimulation are susceptible to ar-
rhythmia recurrence, while inability to induce arrhythmias 
during treatment with an antiarrhythmic agent predicts long-
term protection from that arrhythmia. 
Efficacy. The results of our study show that the efficacy 
of bethanidine in the treatment of life-threatening ventricular 
JACC Vol. 6, No.3 
September 1985:51 O~ 7 
arrhythmias as assessed by programmed electrical stimu-
lation is low. The overall complete response rate to be-
thanidine (6 [10%1 of 59 patient-trials) was lower than rates 
of 24 to 30%, which have been reported (20) for conven-
tional antiarrhythmic agents as assessed by programmed 
electrical stimulation with up to three extrastimuli. In ad-
dition, when an antiarrhythmic agent has such a low efficacy 
rate, day to day variability in the response to programmed 
stimulation may itself be responsible for part of the effects 
noted (21). The incidence of aggravation of arrhythmias 
during bethanidine treatment (four trials [7%]) is compa-
rable with recently reported rates (22,23) for both conven-
tional antiarrhythmic agents and other experimental agents. 
The addition of a second acute loading dose when there 
was no response to the first (that is, increasing the loading 
dose from 20 to 30 mg/kg) did not increase efficacy. There 
was no difference in response rates between patients who 
received acute dose loading as compared with those who 
received divided dose loading. 
When patients were stratified according to their present-
ing arrhythmias, there was no difference in complete plus 
partial response rates in patients with episodes of both sus-
tained ventricular tachycardia and ventricular fibrillation as 
compared with those with just ventricular tachycardia (18 
versus 22%, p = NS) (Table I). However, the 10 patients 
with only ventricular fibrillation appeared to have a higher 
rate of response to bethanidine (40%, two complete and two 
partial responses), though the small number of these patients 
precluded assessment of statistical significance (see later). 
Side effects. The major side effect of bethanidine is 
orthostatic hypotension. This is caused by postganglionic 
blockade of norepinephrine release and reuptake and the 
ensuing decreases in alpha-adrenergic tone and peripheral 
vascular resistance (24). Preliminary studies (3-7) sug-
gested that protriptyline, especially when given chronically 
before bethanidine administration, might be effective in at-
tenuating the hypotensive effects of bethanidine. 
When patients in our study were grouped according to 
bethanidine and protriptyline dosages and dosing methods, 
there were no significant differences in the incidence of 
hypotension between the groups, which ranged from 35 to 
65% (Table 3). Evaluation of higher dosages of bethanidine 
would have been limited by an unacceptable incidence of 
orthostatic hypotension. 
Comparison with other studies. Bethanidine was eval-
uated by Bacaner et al. (3) in 23 patients with ventricular 
arrhythmias refractory to standard medications. Sixteen of 
these patients presented with ventricular fibrillation. Ten 
patients had their arrhythmias successfully controlled with 
bretylium before study with bethanidine. The patients re-
ceived 3 to 30 mg/kg of bethanidine as an oral loading dose 
followed by 10 to 40 mg/kg daily as a maintenance dose. 
All patients also received 15 to 120 mg daily of protriptyline 
to minimize the hypotensive side effects of bethanidine. 
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Fourteen patients underwent noninvasive evaluation of the 
effectiveness of bethanidine, and nine patients also under-
went programmed ventricular stimulation with up to four 
extrastimuli. Spontaneous or induced ventricular arrhyth-
mias were suppressed in 18 (78%) of 23 patients, including 
all 10 patients who had beneficial responses to bretylium. 
Six of the nine patients who underwent stimulation were 
completely protected from induction of their arrhythmias 
while receiving bethanidine. 
In another study by the same group, Benditt et al. (4) 
reported on the efficacy of bethanidine in 14 survivors of 
out of hospital cardiac arrest not associated with myocardial 
infarction. Nine of these patients presented with primary 
ventricular fibrillation and five with sustained ventricular 
tachycardia. Baseline programmed stimulation on no an-
tiarrhythmic agents with up to four extrastimuli induced 
sustained ventricular tachycardia in II patients and non-
sustained ventricular tachycardia in 3 patients. The oral dose 
of bethanidine acutely administered was 16 to 20 mg/kg 
with an additional 10 mg/kg if there was no response to the 
first dose. No ventricular tachycardia or ventricular fibril-
lation was inducible after bethanidine in eight patients (57%) 
(six of eight had presented with ventricular fibrillation), two 
patients had sustained ventricular tachycardia converted to 
nonsustained ventricular tachycardia and four had no re-
sponse to the drug. The doses used in the eight patients 
whose arrhythmias became noninducible were 20 to 30 mg/kg. 
Despite a single initial dose of protriptyline of 10 to 15 mg, 
orthostatic hypotension was "often a major clinical prob-
lem" but reportedly could be managed by manipulation of 
protriptyline dosages. These two studies are comparable 
with our study with respect to bethanidine dosages, pro-
triptyline usage and programmed stimulation technique. 
However, in these studies, patients with ventricular fibril-
lation represented a larger subgroup of patients tested. 
In another report (5,6) of 20 patients undergoing ven-
tricular stimulation because of symptomatic ventricular 
tachycardia, intravenous bethanidine prevented tachycardia 
induction in 8 patients (40%). Seven of these patients re-
ceived 5 mg/kg and one patient received 10 mg/kg of be-
thanidine. Protriptyline was reported to effectively diminish 
the hypotensive side effects of bethanidine. 
Other issues and limitations. This study evaluated the 
effectiveness of bethanidine in the treatment of ventricular 
tachyarrhythmias as assessed by programmed electrical 
stimulation. Recent studies (25,26) suggested that there are 
differences between ventricular fibrillation and ventricular 
tachycardia that may have important etiologic and thera-
peutic implications: the sympathetic nervous system and 
adrenergic tone may play a significant role in the devel-
opment of ventricular fibrillation. Drugs that have become 
useful in the therapy of ventricular tachycardia have not 
been shown to increase the ventricular fibrillation threshold 
of canine hearts (27). Bretylium and bethanidine, however, 
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have been shown to increase the ventricular fibrillation 
threshold in this type of experimental preparation (2,27). 
Bethanidine is a structural analog of bretylium, and its an-
tiadrenergic effect may explain an apparent preferential ef-
fectiveness in the treatment of ventricular fibrillation (28). 
Our study suggests that when assessed by the response 
to programmed electrical stimulation, bethanidine is not 
very effective for the treatment of ventricular tachyarrhyth-
mias. However, the subgroup of patients with only ven-
tricular fibrillation appeared to have a more favorable re-
sponse rate. The small size of this subgroup may have 
prevented determination of the true response rate to be-
thanidine in these patients. This study differed from previous 
studies (3,4) with a higher response rate to bethanidine in 
that our group had fewer patients with only ventricular fi-
brillation. This may account for some of the decreased 
efficacy. 
In one study (3), all of the patients that had responded 
to bretylium also responded to bethanidine treatment. This 
suggests that bethanidine might be more effective in patients 
who have arrhythmias that are suppressed by bretylium; that 
is, acute testing with bretylium may be useful as a guide 
for further bethanidine therapy. Of the II patients in our 
study who had previously received bretylium, only 3 re-
sponded favorably to bethanidine treatment. Therefore, we 
could not determine that a response to bretylium predicted 
a favorable response to bethanidine. 
Finally, it should be noted that almost all patients in this 
study were actually studied on a combination of oral be-
thanidine and protriptyline. Thus, an interaction between 
these two medications that may have decreased the antiar-
rhythmic efficacy of bethanidine cannot be discounted. 
However, administration of bethanidine without concurrent 
use of protriptyline is clinically unrealistic because of the 
hypotension caused by bethanidine alone. Tricyclic anti-
depressants did not appear to interfere with the claimed 
antiarrhythmic efficacy of bethanidine in two other studies 
(3,5) and, in fact, they may have an antiarrhythmic effect 
(29) or act to increase ventricular fibrillation threshold (30). 
These potential beneficial effects were not evident in this 
study. 
Conclusions. The encouraging results of earlier studies 
evaluating bethanidine for the treatment of ventricular tachy-
cardia and ventricular fibrillation have not been realized in 
this multicenter, prospective trial involving 56 patients. Be-
thanidine prevented arrhythmia induction in only 11 % of 
patients tested. A high incidence of orthostatic hypotension 
was a further drawback to its use. The incidence of hypo-
tension was reduced by concurrent protriptyline adminis-
tration, but a substantial number of patients (54%) still ex-
perienced this side effect. This study could not exclude that 
bethanidine may be more effective in patients who present 
with primary ventricular fibrillation alone or in those who 
have previously manifested a favorable response to bretylium. 
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Appendix 
Multicenter Bethanidine Study: Participating Members 
Vance Plumb, MO, Albert L. Waldo, MD. University of Al-
abama in Birmingham Medical Center, Birmingham. Alabama; 
William 1. Mandel, MO, Angas Hamer, MD. Thomas Peter, MO, 
University of California at Los Angeles, Cedars-Sinai Medical 
Center, Los Angeles. California; Fred Morady, MO, Melvin M. 
Scheinman, MO, University of California at San Francisco, Moffitt 
Hospital, San Francisco, California; Allan Greenspan, MO, Leon-
ard N. Horowitz, MO, Scott R. Spielman, MO, Hahnemann Med-
ical College and Hospital, Philadelphia, Pennsylvania: Robert A. 
Bauernfeind, MO, University of Illinois Hospital, Chicago, Illi-
nois; Edward Platia, MO, Phillip R. Reid, MO, lohns Hopkins 
Hospital, Baltimore, Maryland; Robert 1. Myerburg, MO, Richard 
Trohman, MO, * Liaqat Zaman, MO, University of Miami School 
of Medicine, Miami, Florida; Toby R. Engel, MO, Peter Kowey, 
MO, Medical College of Pennsylvania, Philadelphia, Pennsylva-
nia; lohn O. Fisher, MO, Soo G. Kim, MO, leffrey A. Matos, 
MO, Sam L. Teichman, MO, Lawrence E. Waspe, MO, Mon-
tefiore Medical Center, The Albert Einstein College of Medicine, 
Bronx, New York; lames H. Brinckerhoff, A.H. Robins Com-
pany, Office of Medical Research, Richmond, Virginia; Maurice 
Buchbinder, MO, lay W. Mason, MO, Stanford University Med-
ical Center, Stanford, California; leffrey L. Anderson, MO, Uni-
versity of Utah, LOS Hospital, Salt Lake City, Utah; lohn P. 
DiMarco, MO, University of Virginia Medical Center, Charlottes-
ville, Virginia. 
*Dr. Trohman was also supported by research training Grant HL07436 
in cardiac electrophysiology from the National Heart, Lung, and Blood 
Institute, National Institutes of Health, Bethesda. Maryland. 
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